NCT04120116 - FX-322 in Adults With Stable Sensorineural Hearing Loss | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

October 6, 2020

Study Completion Date

December 17, 2020

Conditions

Sensorineural Hearing LossNoise Induced Hearing LossSudden Sensorineural Hearing Loss

Interventions

DRUG

FX-322 (One Dose)

Patients will receive one dose of FX-322.

DRUG

FX-322 (Two Doses)

Patients will receive two doses of FX-322.

DRUG

FX-322 (Four Doses)

Patients will receive four doses of FX-322.

DRUG

Placebo

Patients will receive Placebo.

Trial Locations (16)

14226

Clinical Trial Site, Amherst

23235

Clinical Trial Site, Richmond

27103

Clinical Trial Site, Winston-Salem

28105

Clinical Trial Site, Matthews

29118

Clinical Trial Site, Orangeburg

33487

Clinical Trial Site, Boca Raton

33612

Clinical Trial Site, Tampa

34239

Clinical Trial Site, Sarasota

40207

Clinical Trial Site, Louisville

68118

Clinical Trial Site, Omaha

78240

Clinical Trial Site, San Antonio

78258

Clinical Trial Site, San Antonio

78705

Clinical Trial Site, Austin

80909

Clinical Trial Site, Colorado Springs

90503

Clinical Trial Site, Torrance

93720

Clinical Trial Site, Fresno